Abivax (ABVX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.68
- EPS estimate
- −$0.92
- EPS surprise
- −83.42%
- Revenue surprise
- +71.96%
- Revenue
- $1.4M
- Revenue estimate
- $799,166.00
- Reported
- Sep 21, 2026
Abivax reported Q2 2026 results on September 21, 2026. The company posted a loss of $1.68 per share, wider than the $0.92 loss expected, a miss of 83.42%. Revenue was $1.4 million against an estimate of about $0.8 million. In Q2 2025 the loss was $0.97 per share on $1.3 million of revenue, so the loss widened by $0.71 per share year over year.
The record here is short. The table holds only six quarters, starting with Q1 2025, and every one of them was a loss. Losses for fiscal 2025 add up to $5.61 per share, with the widest quarterly loss at $2.47 in Q3 2025. Quarterly revenue has stayed small, between about $0.5 million and $2.4 million. The first half of 2026 shows a loss of $2.38 per share, compared with $1.94 in the first half of 2025. Abivax beat the EPS estimate in two of the six quarters, Q4 2025 and Q1 2026.
Report dates have varied in this short record. Q3 2025 results came out on December 15, 2025, which points to around mid-December 2026 for Q3 2026. The next report will show whether the quarterly loss narrows from the Q2 level.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Sep 21, 2026 | −$0.92 | −$1.68 | −83.42% | $1.4M | SEC |
| Q1 2026 | May 22, 2026 | −$0.94 | −$0.70 | +24.89% | $1.5M | SEC |
| Q4 2025 | Mar 23, 2026 | −$1.35 | −$1.20 | +11.02% | $515,064.00 | SEC |
| Q3 2025 | Dec 15, 2025 | −$0.79 | −$2.47 | −214.27% | $2.4M | SEC |
| Q2 2025 | Sep 8, 2025 | −$0.93 | −$0.97 | −4.45% | $1.3M | SEC |
| Q1 2025 | Jun 2, 2025 | −$0.76 | −$0.97 | −28.31% | $1.2M | SEC |
Quarterly revenue
Frequently asked questions
When did Abivax (ABVX) last report earnings?
Abivax last reported on Sep 21, 2026, covering fiscal Q2 2026.
Did ABVX beat earnings estimates?
No. Abivax reported EPS of −$1.68 for Q2 2026 against a −$0.92 estimate — a 83.42% miss.
How much revenue did ABVX report last quarter?
Abivax reported $1.4M in revenue for Q2 2026, against a consensus estimate of $799,166.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.